Abstract
Amyotrophic lateral sclerosis (ALS) is a debilitating neuro-degenerative disorder characterized by progressive loss of motor neurons. The etiology and molecular pathogenesis of cell death in most sub-types of the disease are largely unknown. The best documented cause of moto-neuron degeneration is the mutation in the superoxide dismutase-1 (SOD1) gene, which occurs in 10% of the familial forms of ALS. Discovery of RNA interference (RNAi), which plays an important role in the regulation of gene expression, has proven to be a powerful tool to study the pathogenesis and to develop innovative treatment options for hereditary diseases, including familial variants of ALS. This review summarizes current research advances in RNAi in relation to ALS.
Keywords: Amyotrophic lateral sclerosis (ALS), gene expression, messenger RNA (mRNA), micro RNA (miRNA), RNA interference (RNAi), short (or small) hair-pin RNAs (shRNA), short (or small) interfering RNA (siRNA), superoxide dismutase (SOD), Thomas Tuschl's group, silencer RNAs
Current Drug Metabolism
Title: RNA Interference and Amyotrophic Lateral Sclerosis
Volume: 12 Issue: 7
Author(s): Albert A. Rizvanov, Sukru Gulluoglu, Mehmet E. Yalvac, Andras Palotas and Rustem R. Islamov
Affiliation:
Keywords: Amyotrophic lateral sclerosis (ALS), gene expression, messenger RNA (mRNA), micro RNA (miRNA), RNA interference (RNAi), short (or small) hair-pin RNAs (shRNA), short (or small) interfering RNA (siRNA), superoxide dismutase (SOD), Thomas Tuschl's group, silencer RNAs
Abstract: Amyotrophic lateral sclerosis (ALS) is a debilitating neuro-degenerative disorder characterized by progressive loss of motor neurons. The etiology and molecular pathogenesis of cell death in most sub-types of the disease are largely unknown. The best documented cause of moto-neuron degeneration is the mutation in the superoxide dismutase-1 (SOD1) gene, which occurs in 10% of the familial forms of ALS. Discovery of RNA interference (RNAi), which plays an important role in the regulation of gene expression, has proven to be a powerful tool to study the pathogenesis and to develop innovative treatment options for hereditary diseases, including familial variants of ALS. This review summarizes current research advances in RNAi in relation to ALS.
Export Options
About this article
Cite this article as:
A. Rizvanov Albert, Gulluoglu Sukru, E. Yalvac Mehmet, Palotas Andras and R. Islamov Rustem, RNA Interference and Amyotrophic Lateral Sclerosis, Current Drug Metabolism 2011; 12 (7) . https://dx.doi.org/10.2174/138920011796504464
DOI https://dx.doi.org/10.2174/138920011796504464 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Induced Pluripotent Stem Cell-Based Studies of Parkinson's Disease: Challenges and Promises
CNS & Neurological Disorders - Drug Targets AMPA Receptor Antagonists: Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Pharmacoperones as a New Therapeutic Approach: In Vitro Identification and In vivo Validation of Bioactive Molecules
Current Drug Targets Neuro-Inflammatory Mechanisms in Developmental Disorders Associated with Intellectual Disability and Autism Spectrum Disorder: A Neuro- Immune Perspective
CNS & Neurological Disorders - Drug Targets Protective Effects of Melatonin and Mitochondria-targeted Antioxidants Against Oxidative Stress: A Review
Current Medicinal Chemistry Chronic Cerebrospinal Venous Insufficiency (CCSVI) and Multiple Sclerosis (MS): A Critical Review
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: Amyloid-Associated Disease Mechanisms in Alzheimers Disease (Guest Editor: Jeroen J.M. Hoozemans)]
Current Drug Targets - CNS & Neurological Disorders Microtubule-Directed Therapeutic Strategy for Neurodegenerative Disorders: Starting From the Basis and Looking on the Emergences
Current Pharmaceutical Design Edaravone May Prevent Ferroptosis in ALS
Current Drug Targets Role of Metal Ions in the Aβ Oligomerization in Alzheimers Disease and in Other Neurological Disorders
Current Alzheimer Research A New Interpretative Paradigm for Conformational Protein Diseases
Current Protein & Peptide Science Induced Adaptive Resistance to Nitrooxidative Stress in the CNS: Therapeutic Implications
Central Nervous System Agents in Medicinal Chemistry The Application of Freidinger Lactams and their Analogs in the Design of Conformationally Constrained Peptidomimetics
Current Medicinal Chemistry Inhibitors of Protein-Protein Interactions as Potential Drugs
Current Computer-Aided Drug Design α-Synuclein Misfolding and Neurodegenerative Diseases
Current Protein & Peptide Science Inhibition of Autophagy Potentiated Hippocampal Cell Death Induced by Endoplasmic Reticulum Stress and its Activation by Trehalose Failed to be Neuroprotective
Current Neurovascular Research Flavonoids as Sirtuin Modulators
Current Topics in Medicinal Chemistry Hepatocyte Growth Factor (HGF): Neurotrophic Functions and Therapeutic Implications for Neuronal Injury/Diseases
Current Signal Transduction Therapy Meet Our Editorial Board Member:
Current Alzheimer Research Immunophilins: Structures, Mechanisms and Ligands
Current Molecular Pharmacology